NovoPath adds capabilities to NovoPath 360
Oct. 3, 2022—NovoPath today announced the release of enhanced integrated workflows to its software-as-a-service–based LIS platform, NovoPath 360.
Webinars and Sponsored Roundtables — Register Now
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Industry News
Illumina unveils NovaSeq X series
Sept. 29, 2022—Illumina today announced the launch of the NovaSeq X series—NovaSeq X and NovaSeq X Plus—production-scale sequencers, which aim to enable faster, more powerful, and more sustainable sequencing.
Oncomine Dx Target test approved to ID patients for Retevmo
Sept. 28, 2022—The FDA has approved Thermo Fisher Scientific’s Oncomine Dx Target Test as a companion diagnostic to aid in selecting patients with RET-fusion positive locally advanced or metastatic non-small cell lung cancer, RET-fusion positive advanced or metastatic thyroid cancer, and RET-mutation positive advanced or metastatic medullary thyroid cancer who may be eligible for treatment with Lilly’s Retevmo (selpercatinib).
FDA approves T-Cell Select to automate TB testing
Sept. 22, 2022—Oxford Immunotec, a division of PerkinElmer, announced FDA approval of its T-Cell Select reagent kit for automating the company’s T-SPOT.TB test workflow for in vitro diagnostic use by certified laboratories.
FDA clears Roche Cobas Pure for low- to mid-vol labs
Sept. 19, 2022—Roche received FDA 510(k) clearance for the Cobas Pure, a compact and modular solution that combines clinical chemistry, immunoassay, and ion-selective electrode diagnostic testing on a single platform with a footprint of about 21 square feet.
FDA clears DiaSorin Simplexa COVID-19 test
Sept. 14, 2022—DiaSorin received 510(k) clearance from the FDA for its Simplexa COVID-19 Direct kit.
NovoPath, FrontRunnerHC to extend NovoPath 360 capabilities
Sept. 7, 2022—NovoPath has signed a resellers agreement with FrontRunnerHC, a software provider that aims to help health care organizations maximize reimbursements with data automation solutions that provide accurate patient demographic, insurance, and financial information.
Specific Reveal AST system designated a breakthrough device
Aug. 24, 2022—BioMérieux announced that its Specific Reveal rapid antimicrobial susceptibility test system has received a breakthrough device designation from the FDA.
Guardant360 CDx OK’d as companion diagnostic for Enhertu
Aug. 23, 2022–Guardant Health announced that the FDA has approved its Guardant360 CDx liquid biopsy test as a companion diagnostic to select patients with unresectable or metastatic HER2 (ERBB2)-mutant non-small cell lung cancer whose tumors have activating HER2 mutations (single nucleotide variants and exon 20 insertions) for treatment with Enhertu
Roche’s COVID-19 test detects, differentiates BA.2.75
Aug. 22, 2022—Roche and its subsidiary TIB Molbiol have developed a COVID-19 test for researchers that detects and differentiates the BA.2.75 subvariant.